Literature DB >> 18493922

Medical management of thyroid cancer: a risk adapted approach.

R Michael Tuttle1, Rebecca Leboeuf, Ashok R Shaha.   

Abstract

Risk adapted treatment recommendations are dependent on accurate predictions of the risk of recurrence, risk of death, and likely sites of recurrence. When combined with response to therapy assessments and secondary risk stratification during follow-up, this risk adapted approach will allow the clinician to tailor the aggressiveness of therapy and follow up to the risk of recurrence and death in individual patients. Copyright (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18493922     DOI: 10.1002/jso.21010

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

Review 1.  Well differentiated thyroid carcinoma: current treatment.

Authors:  J Kenneth Byrd; Robert J Yawn; Christina S T Wilhoit; Nicoleta D Sora; Linda Meyers; Jyotika Fernandes; Terry Day
Journal:  Curr Treat Options Oncol       Date:  2012-03

2.  Continuous re-evaluation in differentiated thyroid carcinoma.

Authors:  Frederik A Verburg; Christoph Reiners
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

3.  Controversies and challenges in the management of well-differentiated thyroid cancer.

Authors:  N Gopalakrishna Iyer; Ashok R Shaha
Journal:  Indian J Surg       Date:  2010-01-13       Impact factor: 0.656

Review 4.  Radioiodine for remnant ablation and therapy of metastatic disease.

Authors:  Christoph Reiners; Heribert Hänscheid; Markus Luster; Michael Lassmann; Frederik A Verburg
Journal:  Nat Rev Endocrinol       Date:  2011-08-09       Impact factor: 43.330

5.  Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure.

Authors:  Laura Y Wang; Ronald Ghossein; Frank L Palmer; Iain J Nixon; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly
Journal:  Thyroid       Date:  2015-07-30       Impact factor: 6.568

6.  Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up.

Authors:  Frank Berger; Ulla Friedrich; Peter Knesewitsch; Klaus Hahn
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-11-18       Impact factor: 9.236

7.  Mortality-related factors in 1056 radioiodine-treated patients with well-differentiated thyroid cancer in southern Thailand.

Authors:  Tada Yipintsoi; Teerapon Premprabha; Alan Geater; Tanyaluck Thientunyakij; Suchitra Thongmak
Journal:  World J Surg       Date:  2010-02       Impact factor: 3.352

8.  No survival difference after successful (131)I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer.

Authors:  Frederik Anton Verburg; Marcel P M Stokkel; Christian Düren; Robbert B T Verkooijen; Uwe Mäder; Johannes W van Isselt; Robert J Marlowe; Johannes W Smit; Christoph Reiners; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-11-29       Impact factor: 9.236

9.  The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma.

Authors:  Elena-Daphne Thies; Karina Tanase; Uwe Maeder; Markus Luster; Andreas K Buck; Heribert Hänscheid; Christoph Reiners; Frederik A Verburg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-17       Impact factor: 9.236

10.  Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer.

Authors:  Ana B Santoro; Daniela D Vargens; Mateus de Camargo Barros Filho; Daniel A Bulzico; Luiz Paulo Kowalski; Ricardo M R Meirelles; Daniela P Paula; Ronaldo R S Neves; Cencita N Pessoa; Claudio J Struchine; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.